Subscribe
michael-vi-johnson-johnson
Michael Vi / Shutterstock
27 July 2023Liz Hockley

J&J awarded $18m in fake surgical devices case

Judge enters default judgment and permanent injunction order after defendant failed to show in court | Alleged counterfeit medical tools were being sold under Ethicon brand.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J agrees Stelara deals with generics
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
J&J settles Amgen clash over blockbuster psoriasis drug
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Medtech
Intuitive resolves robotic surgery dispute with J&J unit
10 August 2023   Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
J&J agrees Stelara deals with generics
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
J&J settles Amgen clash over blockbuster psoriasis drug
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Medtech
Intuitive resolves robotic surgery dispute with J&J unit
10 August 2023   Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.

More on this story

Americas
J&J agrees Stelara deals with generics
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
J&J settles Amgen clash over blockbuster psoriasis drug
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Medtech
Intuitive resolves robotic surgery dispute with J&J unit
10 August 2023   Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers